Egypt Liver Cancer Therapeutics Market Report 2022 to 2030

Egypt Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Egypt liver cancer therapeutics market will reach a value of $33.2 Mn from $8.2 Mn in 2022, growing at a CAGR of 19.1% during 2022-30. The liver cancer therapeutics market in Egypt is dominated by a few domestic pharmaceutical companies such as Pharco Pharmaceuticals, EIPICO, and Memac Pharma. The liver cancer therapeutics market in Egypt is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10EGPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Egypt AUTHOR: Dr. Vishwa Modhia

Buy Now

Egypt Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Egypt liver cancer therapeutics market will reach a value of $33.2 Mn from $8.2 Mn in 2022, growing at a CAGR of 19.1% during 2022-30.

Egypt is a lower middle-income, developing country in North Africa that borders the Red Sea and the Mediterranean Sea. Cancer patients in Egypt are treated at the General Authority for Health Insurance hospitals, the Ministry of Health and Population hospitals, or university hospitals at the government's expense, or in the private sector at their own expense or with personal insurance coverage. Non-governmental organizations also assist cancer patients in a variety of ways, including financial support for government hospitals, treatment services in their facilities, and direct emotional support to patients. Around 80% of all gastrointestinal malignancies in Egypt were of liver origin, with alcohol being a major contributing factor.

According to the most recent WHO data published in 2020, the number of people dying from liver cancer in Egypt reached 24,512, accounting for 4.57 % of all deaths. Egypt ranks second in the world with an age-adjusted death rate of 34.11 per 100,000 inhabitants. Egypt's government spent 4.4 % of its GDP on healthcare in 2020.

egypt liver cancer therapeutics market

Market Dynamics

Market Growth Drivers

The country boasts more oncology-trained medical staff and a more modern infrastructure for cancer diagnosis, surgical treatment, systemic therapy, and radiotherapy treatments than other African countries. Egypt has seen major advances in liver cancer therapies in recent years. The advent of targeted medicines such as sorafenib and lenvatinib, which are effective in treating advanced HCC, has been one of the important growth reasons. Furthermore, progress has been made in the development of immunotherapies for liver cancer, with medications like nivolumab and pembrolizumab showing promise in clinical trials. Egypt benefits from a favourable geopolitical position as a result of the Suez Canal.

Market Restraints

Egypt's regulatory framework for medication research and licencing may be laxer than in other countries, leading to scepticism about the safety and efficacy of several liver cancer treatments. Despite the government's efforts in healthcare, the amount of funding available for individual research programmes remains restricted. This can make obtaining the necessary finances for research and development of new liver cancer treatments difficult.

Competitive Landscape

Key Players

Pharco Pharmaceuticals - Pharco Pharmaceuticals is an Egyptian pharmaceutical company that focuses on the development and production of a wide range of generic medicines, including oncology drugs
EIPICO - EIPICO is another Egyptian pharmaceutical company that specializes in the development and production of generic medicines, including oncology drugs
Holding Company for Biological Products and Vaccines (VACSERA) - VACSERA is an Egyptian state-owned biotechnology company that develops and produces a wide range of products, including vaccines and cancer therapeutics
Memac Pharma - Memac Pharma is an Egyptian pharmaceutical company that develops and produces a range of medicines, including oncology drugs
Egypt Pharmed Healthcare - Egypt Pharmed Healthcare is an Egyptian pharmaceutical company that produces a range of medicines, including oncology drugs

Recent Notable Updates

March 2022: Egypt's Ministry of Health and Population started an effort targeted at the early detection of liver cancer and treatment of cirrhosis patients. The examination includes cancer marker tests and ultrasound scanning, according to the ministry. Medicines for liver cancer are accessible in 22 ministry and university hospitals connected with the National Committee for Control of Viral Hepatitis (NCCVH).

Healthcare Policies and Reimbursement Scenarios

The Egyptian Drug Authority (EDA) oversees the regulation of liver cancer therapies in Egypt. The EDA is responsible for examining the safety, efficacy, and quality of all medicines, including those used to treat liver cancer. In terms of reimbursement, Egypt has a public healthcare system that covers a variety of liver cancer therapies such as chemotherapy, targeted therapy, and immunotherapy.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Egypt Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.